Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period (https://ibn.fm/viChU). However, during the same timeframe, approximately 4,500 new deaths were reported, marking a 28% increase. This underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments.
In the United States, the Centers for Disease Control and Prevention (“CDC”) reported that as of April 11, 2025, the levels of acute respiratory illnesses, including COVID-19, remain low (https://ibn.fm/tTcxB). Nevertheless, the virus continues to circulate, and the potential for new variants necessitates ongoing vigilance. The fluctuating nature of COVID-19 cases and the emergence of variants highlight the critical need for continued research and development of safe and effective vaccines and therapeutics.
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is addressing this need through the development of CiVax(TM), a heat-stable COVID-19 subunit vaccine candidate. Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants (https://ibn.fm/umdje). In nonhuman primate studies, a booster dose of CiVax elicited a swift and robust neutralizing antibody response, enhancing protection against SARS-CoV-2, including the Delta and Omicron variants.
“The CiVax vaccine has demonstrated broad and robust immune responses in mice, which has been recapitulated in nonhuman primates and further shown to yield protection against infection with COVID-19 variants of concern,” observed Dr. Axel Lehrer, an associate professor at the University of Hawaiʻi at Mānoa and lead investigator in the CiVax studies. This highlights the potential of CiVax to serve as a versatile tool in the ongoing fight against COVID-19.
Soligenix’s innovative approach focuses on developing a more cost-effective vaccine that not only provides protection against multiple variants but is also thermostable, eliminating the need for cold chain storage. This characteristic is particularly advantageous for global distribution, ensuring that vaccines remain viable in regions with limited refrigeration infrastructure.
The continued prevalence of COVID-19 and the emergence of new variants underscore the importance of advancing vaccine technologies. Soligenix’s CiVax represents a promising development in this context, offering the potential for more cost-effective, broad-spectrum protection while having the logistical advantages that could significantly contribute to global vaccination efforts.
For more information, visit www.Soligenix.com.
NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams…
Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether…
Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology…
For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients…
Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis)…
According to a new survey, approximately 60% of workers in the U.S. healthcare sector are…